These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
3. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. Katase K; Sugiyama Y; Hasumi K; Yoshimoto M; Kasumi F Cancer; 1998 May; 82(9):1698-703. PubMed ID: 9576291 [TBL] [Abstract][Full Text] [Related]
4. Indication of hysteroscopy in tamoxifen treated breast cancer patients. Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527 [TBL] [Abstract][Full Text] [Related]
5. Relationship between tamoxifen use and high risk endometrial cancer histologic types. Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966 [TBL] [Abstract][Full Text] [Related]
6. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : comparison of cohorts treated with and without tamoxifen. Saadat M; Truong PT; Kader HA; Speers CH; Berthelet E; McMurtrie E; Olivotto IA Cancer; 2007 Jul; 110(1):31-7. PubMed ID: 17510927 [TBL] [Abstract][Full Text] [Related]
7. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Cheng WF; Lin HH; Torng PL; Huang SC Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568 [TBL] [Abstract][Full Text] [Related]
8. Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer. Rieck GC; Freites ON; Williams S J Obstet Gynaecol; 2005 Jan; 25(1):39-41. PubMed ID: 16147692 [TBL] [Abstract][Full Text] [Related]
9. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen]. Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205 [TBL] [Abstract][Full Text] [Related]
10. Endometrial cancer in patients with breast carcinoma treated with tamoxifen: report of two cases and the literature overview. Sliwińska M; Wojtacki J; Sliwiński W Med Sci Monit; 2000; 6(2):399-406. PubMed ID: 11208346 [TBL] [Abstract][Full Text] [Related]
11. Endometrial cancer after tamoxifen treatment: a descriptive study of 25 breast cancer patients who subsequently developed endometrial cancer. Peters-Engl C; Medl M; Danmayr E; Mirau M; Alth G; Leodolter S Anticancer Res; 1996; 16(5B):3241-6. PubMed ID: 8920798 [TBL] [Abstract][Full Text] [Related]
12. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Robinson DC; Bloss JD; Schiano MA Gynecol Oncol; 1995 Nov; 59(2):186-90. PubMed ID: 7590470 [TBL] [Abstract][Full Text] [Related]
13. [Adjuvant therapy of breast cancer with tamoxifen and endometrial carcinoma]. Mignotte H; Sasco AJ; Lasset C; Saez S; Rivoire M; Bobin JY Bull Cancer; 1992; 79(10):969-77. PubMed ID: 1292764 [TBL] [Abstract][Full Text] [Related]
14. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. Swerdlow AJ; Jones ME; J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574 [TBL] [Abstract][Full Text] [Related]
15. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Beiner ME; Finch A; Rosen B; Lubinski J; Moller P; Ghadirian P; Lynch HT; Friedman E; Sun P; Narod SA; Gynecol Oncol; 2007 Jan; 104(1):7-10. PubMed ID: 16962648 [TBL] [Abstract][Full Text] [Related]
16. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Slomovitz BM; Sun CC; Ramirez PT; Bodurka DC; Diaz P; Lu KH Obstet Gynecol; 2004 Aug; 104(2):255-60. PubMed ID: 15291996 [TBL] [Abstract][Full Text] [Related]
17. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. Mariotto AB; Feuer EJ; Harlan LC; Abrams J J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888 [TBL] [Abstract][Full Text] [Related]
18. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers. Hachisuga T; Saito T; Kigawa J; Ohwada M; Yamazawa K; Yasue A; Iwasaka T; Sugiyama T; Kita T; Nagai N Gynecol Oncol; 2004 Oct; 95(1):139-44. PubMed ID: 15385123 [TBL] [Abstract][Full Text] [Related]
20. The nature of tamoxifen action in the control of female breast cancer. Kodama M; Kodama T In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]